New chemo sequence aims to make pancreatic tumors operable
NCT ID NCT05825066
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether giving two different chemotherapy regimens one after the other can shrink pancreatic tumors that are borderline or locally advanced, making them easier to remove surgically. The study enrolls 64 adults with pancreatic adenocarcinoma. Participants first receive gemcitabine plus nab-paclitaxel for one month, then switch to mFOLFIRINOX for another month, before being evaluated for surgery. The main goal is to see how many patients achieve a clean surgical margin (R0 resection).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gemcitabine, nab-paclitaxel (Abraxane), and mFOLFIRINOX (a combination of four chemotherapy drugs)
What this could lead to
If this sequence works, it could help shrink pancreatic tumors enough to allow more patients to have successful surgery, potentially improving survival.
What could go wrong
This is a small, early-phase trial with only 64 participants. The sequence is experimental and may not be more effective than standard treatment, and chemotherapy carries significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••